The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women

• Published in: Fertility and sterility Vol. 48; no. 4; pp. 555 - 559
• Main Authors: Hesla, John S., Rodman, Elise F., Molitch, Mark E., Goodman, Lisa A., Jeffrey Chang, R.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.10.1987; Elsevier Science
• Subjects: Adenoma - complications; Adult; Biological and medical sciences; Ergolines - administration & dosage; Ergolines - therapeutic use; Female; Hormones. Endocrine system; Humans; Hyperprolactinemia - drug therapy; Hyperprolactinemia - etiology; Hyperprolactinemia - physiopathology; Kinetics; Medical sciences; Menstruation Disturbances - drug therapy; Pharmacology. Drug treatments; Pituitary Neoplasms - complications; Prolactin - secretion; Endocrinopathy; Human; Protein hormone; Chemotherapy; Treatment; Prolactin; Hyperprolactinemia; Pituitary diseases; Dopamine agonist; Hormonal investigation
• ISSN: 0015-0282; 1556-5653
• DOI: 10.1016/S0015-0282(16)59463-1

Twelve hyperprolactinemic women were administered the α aminoergoline derivative, CU 32-085 (Sandoz, Inc., East Hanover, NJ), in order to determine its effect on prolactin (PRL) secretion. The mean pretreatment serum PRL level was 145.0 ± 11.5 ng/ml. Significant declines of serum PRL occurred with total daily doses of CU 32-085 of 0.1 to 0.5 mg (P < 0.001). The magnitude of response to therapy was dose-related. In six patients, PRL levels were reduced to less than 25 ng/ml; this effect lasted at least 24 hours after intake of a single dose. In the other six patients, the response was less dramatic. No subjects developed adverse cardiovascular side effects. The results of this study demonstrate that CU 32-085 exhibits a clinically significant dopaminomimetic action on PRL secretion in hyperprolactinemic women.